Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Physicians (Germany)(?)

Council Members in this Study Group: 1137

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Volker Hoffmann, MD, Partner/Owner, Diagnostic Imaging CenterVolker Hoffmann, MD
Partner/Owner
Diagnostic Imaging Center

Volker Hoffmann, MD, is a Diagnostic and Interventional Radiologist and one of the three owners of Diagnostic Imaging Center, a large private imaging center....

Hossein Ghofrani, MD, Physician, Justus Liebig Universitat GiessenHossein Ghofrani, MD
Physician
Justus Liebig Universitat Giessen

Hossein Ardeschir (Ardi) Ghofrani, MD, is Lead physician of the Pulmonary Hypertension Centre at the University of Giessen Lung Center (UGLC), Germany. Prof. Ghofrani is a Reviewer for various high impact scientific journals including Lancet, AJRCCM, Circulation, and Circulation research amongst others....

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Studies favor new Amgen drug for osteoporosis - will the patients like to inject denosumab? | 04-14-2008
Analysis of: Amgen Drug Helps Bones | online.wsj.com
Author: GLG Expert Contributor

Postmenopausal osteoporosis is a real problem for a huge number of the older aged patients, and the population is aging. In daily orthopaedic praxis, I see a lot of osteoporosis related fractures of the wrist, the hip, and the vertebral column. Just yesterday, I operated a pseudarthrosis in the femoral...

Analysis of CRx-191 in Psoriasis - Comments | 11-12-2007
Author: GLG Expert Contributor

The combination of a topical steroid with an antidepressant seems to be intriguing. Antidepressant have shown some anti-pruritic activity in atopic dermatitis. The major disadvantage of the current investigational drug is the sue with occlussive dressings. That makes it impossible to use the drug for...

Bone substitute | 11-09-2007
Author: GLG Expert Contributor

The presented bone substitute is comparable to 240 others in Germany. Only a few bone substitutes differ by bone induction like (DBM(R) Synthes) or (Grafton). Osteoconductive bone substitutes are very common. Only PerOssal(R) by aap, also osteoconductive,  is  selectively  loadable ...

NSF (Nephrogenic Systemic Fibrosis) - Gadoxetic Acid (Primovist) | 10-09-2007
Author: Volker Hoffmann, MD, Partner/Owner, Diagnostic Imaging Center

Nephrogenic systemic fibrosis is becoming a severe problem for radiologist and industry as it may prevent physicians from using gadolinium containing contrast agents fearing that they induce nephrogenic systemic fibrosis even in patients without known kidney disease. A stable contrast agent with almost...

New drug for superficial bladder cancer with better perspectives as the actual standards? Study design will be the most important aspect to get an approval for EOquin from Spectrum Pharmaceuticals. | 09-13-2007
Author: GLG Expert Contributor

The phase 2 trial data presents results with a better outcome for superficial bladder cancer patients as those treated with standard procedures. A complete remission result after 2 years of 67% is dramatically better then adjuvant Chemoinstillation of immune therapy by BCG. The most important question...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Academic Institution*

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Division Head
  • Physician - Director
  • Physician - Department Chair
  • Owner

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-10-10T21:45:17.060